Rheumatoid Arthritis Drug Could Put Brakes on Type 1 Diabetes
THURSDAY, Dec. 7, 2023 -- A drug long used to curb rheumatoid arthritis may be a potent foe against another immune disorder, type 1 diabetes.Australian researchers report that baricitinib (Olumiant) appears to help patients newly diagnosed with... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 7, 2023 Category: General Medicine Source Type: news
Rheumatoid Arthritis Drug, Baricitinib (Olumiant), Could Put Brakes on Type 1 Diabetes
THURSDAY, Dec. 7, 2023 -- A drug long used to curb rheumatoid arthritis may be a potent foe against another immune disorder, type 1 diabetes.
Australian researchers report that baricitinib (Olumiant) appears to help patients newly diagnosed with... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 7, 2023 Category: General Medicine Source Type: news
Hope for hundreds of thousands with type 1 diabetes as major study reveals arthritis drug can suppress the condition
In a world-first clinical trial, researchers in Australia found that baricitinib can preserve the body's own insulin production. (Source: the Mail online | Health)
Source: the Mail online | Health - December 6, 2023 Category: Consumer Health News Source Type: news
Improvements With Guselkumab in Psoriatic Arthritis Seen Across All MDA Domains
(MedPage Today) -- At the American College of Rheumatology annual meeting, results from the phase IIIb COSMOS trial were presented that examined the association between patient- and physician-reported domains and minimal disease activity (MDA... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - December 6, 2023 Category: Rheumatology Source Type: news
Deucravacitinib Improves Joint Symptoms in Psoriatic Arthritis
(MedPage Today) -- Patients with plaque psoriasis who screened positive for psoriatic arthritis in the POETYK PSO-1 and POETYK PSO-2 trials reported greater improvements in joint activity and joint pain scores when treated with deucravacitinib... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - December 6, 2023 Category: Dermatology Source Type: news
Key Data on Psoriatic Arthritis From ACR 2023 Key Data on Psoriatic Arthritis From ACR 2023
Key data on psoriatic arthritis from ACR 2023 include treatment studies examining izokibep, apremilast, and TAK-279, as well as analysis of treatment response and difficult-to-treat cases.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 6, 2023 Category: Consumer Health News Tags: Rheumatology ReCAP Source Type: news
Deucravacitinib Improves Joint Symptoms in Psoriatic Arthritis
(MedPage Today) -- Patients with plaque psoriasis who screened positive for psoriatic arthritis in the POETYK PSO-1 and POETYK PSO-2 trials reported greater improvements in joint activity and joint pain scores when treated with deucravacitinib... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - December 5, 2023 Category: Dermatology Source Type: news
PsA Raises Mortality Risk, but Unevenly
(MedPage Today) -- Swedes with psoriatic arthritis (PsA) tended to die earlier than other people, a national case-control study indicated, but the risk varied considerably among different subgroups.
Overall all-cause mortality was 11% higher for... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - December 4, 2023 Category: Dermatology Source Type: news
Four JAK Inhibitors Have Comparable Efficacy, Safety for RA
FRIDAY, Dec. 1, 2023 -- For patients with rheumatoid arthritis, the efficacy and safety of four Janus kinase (JAK) inhibitors is comparable, according to a study published online Nov. 1 in Rheumatology.
Shinya Hayashi, M.D., from the Kobe... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 1, 2023 Category: Pharmaceuticals Source Type: news
Ins and Outs of Rheumatoid Arthritis
In the webinar, Stanley B. Cohen, MD, broke down all things RA including what boosts your chances of having it, what risks come with RA, and more. (Source: WebMD Health)
Source: WebMD Health - December 1, 2023 Category: Consumer Health News Source Type: news
Asheville Arthritis & amp; Osteoporosis Center Partners with House Rx to Enhance Patient Care Through Medically Integrated Dispensing
Asheville Arthritis & Osteoporosis Center, a community rheumatology clinic based in North Carolina, will be adopting a new care model aimed at improving patient access to life-improving specialty medications. Asheville Arthritis & Osteoporosis Center will provide patients with faster and... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 1, 2023 Category: Pharmaceuticals Tags: LIC Source Type: news
New Data on Bimekizumab in Psoriatic Arthritis
(MedPage Today) -- At the American College of Rheumatology annual meeting, new data was presented on the long-term safety and efficacy of bimekizumab (Bimzelx), a dual interleukin (IL)-17A/F inhibitor, in active psoriatic arthritis.
In this second... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - November 30, 2023 Category: Dermatology Source Type: news
DMARDs Linked to Reduced Thyroid Disease Incidence DMARDs Linked to Reduced Thyroid Disease Incidence
In a large Swedish rheumatoid arthritis cohort, the incidence of thyroid disease declines after RA diagnosis vs the general population, with the effect strongest among those treated with anti-rheumatic drugs.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - November 29, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Could Correcting Metabolic Dysfunction Treat Rheumatoid Arthritis?
(MedPage Today) -- Alterations in tryptophan metabolism are common among patients with rheumatoid arthritis (RA), researchers found, and preclinical studies suggest that correcting them is a viable treatment strategy.
Participants in France's... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - November 28, 2023 Category: Rheumatology Source Type: news
Biologic Therapy for IBD Not Tied to Higher Risk of Major Heart Events
(MedPage Today) -- In contrast to recent data on tofacitinib (Xeljanz) in rheumatoid arthritis, patients with inflammatory bowel disease (IBD) who received biologic therapies appeared to have a lower risk for a major adverse cardiovascular event... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 28, 2023 Category: Gastroenterology Source Type: news
